Scientists target tumor suppressor as a new treatment approach to 'triple-negative' breast cancer

A study analysing the features of “triple-negative” breast cancer has found that the loss of a specific tumor suppressor provides clues about potential new treatment approaches.

Credit: Fotos593/ Shutterstock.com

The analysis, which was conducted by researchers from the University of Arizona and Cancer Research UK, showed that triple-negative breast cancer that is deficient in the retinoblastoma (RB) tumor suppressor is susceptible to drugs that target certain proteins key to cell division and DNA replication. The findings are published in the journal Cell Reports.

Triple-negative breast cancers lack three receptors that can be targeted by drugs, meaning treatment options are currently limited to radiotherapy or chemotherapy.

The lack of a personalized strategy to apply medicine based on specific features of a patient's tumor remains one of the seminal therapeutic challenges in the treatment of triple-negative breast cancer, therefore, exploiting the loss of RB could represent a significant conceptual change in the way we consider treatment."

Adnieszka Witkiewicz, the University of Arizona Cancer Center

Witkiewicz and team had previously established that approximately 20 to 30% of triple-negative breast cancers have lost the RB tumor suppressor. Wondering whether the loss of RB could serve as a drug target, the researchers performed a search for agents that could target RB-deficient triple-negative breast cancers.

They found that the tumors were susceptible to drugs that target two proteins called and AURK, which are key drivers of cell divisions, as well as a protein called CHK1, which is needed for DNA replication. These proteins can serve as tumor biomarkers, properties of the cancer that clinicians can measure in the blood to find out more about how best to treat it.

The researchers found that RB-deficient triple-negative breast tumors expressed higher levels of these biomarkers. Developing drugs that could target these biomarkers may represent a new strategy for treating this 20 to 30% of triple-negative breast cancer patients.

"These studies underscore the importance of understanding fundamental features of tumor cell division and delineating how to target tumor-specific vulnerabilities with new drugs to exploit those events therapeutically," says Erik Knudsen, professor of medicine at the University of Arizona College of Medicine.

The team is now planning to investigate PLK1, AURK and CHK1 inhibitors in clinical trials to test the effectiveness of drugs that target RB-deficient triple-negative breast cancer.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 17). Scientists target tumor suppressor as a new treatment approach to 'triple-negative' breast cancer. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20180206/Scientists-target-tumor-suppressor-as-a-new-treatment-approach-to-triple-negative-breast-cancer.aspx.

  • MLA

    Robertson, Sally. "Scientists target tumor suppressor as a new treatment approach to 'triple-negative' breast cancer". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20180206/Scientists-target-tumor-suppressor-as-a-new-treatment-approach-to-triple-negative-breast-cancer.aspx>.

  • Chicago

    Robertson, Sally. "Scientists target tumor suppressor as a new treatment approach to 'triple-negative' breast cancer". News-Medical. https://www.news-medical.net/news/20180206/Scientists-target-tumor-suppressor-as-a-new-treatment-approach-to-triple-negative-breast-cancer.aspx. (accessed June 20, 2024).

  • Harvard

    Robertson, Sally. 2019. Scientists target tumor suppressor as a new treatment approach to 'triple-negative' breast cancer. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20180206/Scientists-target-tumor-suppressor-as-a-new-treatment-approach-to-triple-negative-breast-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel Concepts Medical's plant-based formula achieves 99% reduction in cancer cell viability